THE TRUE DOSE BOARD

DJAVAD HEDAYATI

CHAIRMAN & CO-FOUNDER

  • As the Chairman and Co-founder of True Dose, I’m dedicated to pushing the boundaries of personalized medicine to ensure every patient receives the right treatment, at the right time, in the right dose. My journey began as a Partner and Board Member at Netlight Consulting, where I helped grow the company from 40 to over 2,000 people across 11 offices in Europe, by fostering a culture of collaboration, innovation, and impact.

    With a background in Computer Science, I’ve always been driven by the challenge of solving complex problems. I co-founded True Dose after discovering that only 45% of cancer patients receive the correct dose of medication—leading to either unnecessary suffering from toxic side effects or the heartbreaking return of the disease. True Dose aims to rewrite this reality and become a cornerstone in the future of truly personalized medicine.

    What sets True Dose apart is the strength of our founding team. While True Dose is a young company, it stands on more than a decade of rigorous research and development carried out by the team. Our collective expertise ensures that we’re building something that is not only innovative but scientifically robust and impactful.

    True Dose is not just another startup—we are on a mission to fundamentally improve patient outcomes through precision medicine. We are looking to collaborate with partners who share our commitment to transforming healthcare. By working with us, you’ll be part of an innovative approach that not only enhances treatment for patients but also streamlines the way healthcare providers and pharmaceutical companies approach drug dosing. Together, we can drive forward a solution that has the potential to save lives and improve the quality of care worldwide.

GUSTAF ERIKSSON

INVESTOR AND BOARDMEMBER

  • I am an entrepreneur with over 20 years of experience in founding and developing successful companies across various industries. My expertise lies in a deep understanding of business – from building and scaling companies to creating products and services that truly resonate with the market. Regardless of the sector, my strength has always been identifying business opportunities and transforming them into sustainable ventures.

    With experience spanning over multiple industries, my focus has always been on understanding customer needs. A key aspect of my entrepreneurial journey has been creating solutions that are not only commercially successful, but also make a real difference in people's lives. This is what drives my commitment to True Dose.

    My goal with True Dose is to make a meaningful impact on people who find themselves in difficult situations by providing them with better opportunities to receive the right treatment. By developing innovative solutions that improve precision and effectiveness in treatments, I strive to create a product that helps patients get the care they deserve, benefiting both them and the healthcare system as a whole.

    One of my core strengths is building strong relationships with investors and financial stakeholders, which I see as essential for driving companies forward and ensuring long-term success. With my broad experience in taking companies from concept to market, and my ability to create value for both customers and stakeholders, I am excited to contribute to True Dose’s success and to improving people’s lives through better healthcare solutions.

RICKARD HENZE

INVESTOR AND BOARDMEMBER

  • As a current board member of True Dose, I am deeply committed to the company's mission of revolutionizing healthcare through innovative medical technology. With my extensive background in financial services, consulting, and leadership roles across various industries, I am thrilled to be part of an organization that has such a tangible impact on patient outcomes and the broader healthcare landscape.

    My experience serving on multiple boards has strengthened my understanding of effective corporate governance and strategic growth in fast-paced, high-regulation sectors. What excites me most about True Dose is its unique position at the forefront of medtech innovation, a field where precision, reliability, and technological advancements are not just beneficial but life-saving.

    Having worked in financial leadership roles, such as Head of Equity Research and Senior Director of Portfolio Management at Nordea, I bring a strategic perspective on growth and financial sustainability. I am passionate about ensuring that True Dose remains both innovative and operationally sound as it scales. My entrepreneurial experience as co-founder of Oxdjupet Förvaltning has also deepened my ability to navigate complex challenges while fostering a culture of excellence.

    Being part of True Dose’s journey is incredibly rewarding, and I am more dedicated than ever to contributing my skills and insights to help the company achieve its full potential. The opportunity to shape the future of healthcare through cutting-edge science is what drives my passion and continued commitment as a board member.

ELHAM HEDAYATI

CO-FOUNDER

  • I am an Associate Professor and Clinical Oncologist with over 20 years of experience. I’m known for my solution-oriented mindset and a positive outlook, even in challenging situations. I thrive on finding practical solutions to complex problems and am passionate about improving patient care.

    My academic journey began with medical school, followed by a PhD and residency in clinical oncology. Early on, I developed a profound interest in oncology, which shaped my career and academic pursuits.

    I co-founded True Dose in response to challenges faced during a clinical trial, particularly in patient recruitment due to complex blood sampling logistics. True Dose presented a patient-centered solution that aligned perfectly with my goals for the trial.

    Looking ahead, I hope True Dose will become a staple in clinical routines and trials, enabling precise dose adjustments through enhanced pharmacodynamic data. Our aim is to significantly improve patient outcomes by personalizing treatment.

    The decision to start True Dose was driven by the need for a patient-centric blood sampling solution. Our technology bridges the gap for drugs requiring Therapeutic Drug Monitoring (TDM), offering a practical alternative to traditional venous blood samples and enhancing the overall patient experience.

PER RYDBERG

CO-FOUNDER & HEAD OF R&D

  • I have a PhD in Environmental Chemistry and the driving force behind True Dose R&D department. What I value most about myself is my passion for tackling new challenges, my persistence, and my ability to blend intellect with humor when solving problems.

    My academic journey began with a degree in Chemistry from Stockholm University. I’ve always been fascinated by the molecular interactions that underpin chemical reactions and their effects on living organisms. This intrigue guided my studies and career.

    I co-founded True Dose to bring our vision of advanced blood sampling technology to life. Our goal was to create a device that simplifies therapeutic drug monitoring (TDM), making it more accessible and practical.

    Looking forward, I hope to navigate the challenges typical of startups and see our innovative products gain acceptance and make a significant impact. We aim to revolutionize how blood sampling is done, benefiting both patients and healthcare providers globally.

    The decision to start True Dose stemmed from a desire to address a critical gap in healthcare. Observing the limitations of existing blood sampling methods, We saw an opportunity to innovate and develop a solution that could truly benefit the global medical community.